{"denoms":[{"counts":[{"groupId":"BG000","value":"30"}],"units":"Participants"}],"groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023.","id":"BG000","title":"Multiple Myeloma/Blenrep Participants"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"45","upperLimit":"87","value":"68"}]}]}],"description":"Age at Treatment Initiation (Baseline)","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"43","upperLimit":"85","value":"61"}]}]}],"description":"Age at Multiple Myeloma Diagnosis","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"29"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}],"title":"Medicare + Commercial"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Medicare + Military"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Medicare + Medicaid"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Commercial Alone"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Medicaid Alone"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Current Payer type","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"At Duke"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"External Location"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Diagnosis Location","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}],"title":">= 10% Bone Marrow Plasma Cells"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Plasmacytoma (Total)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Bone Plasmacytoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Extramedullary Plasmacytoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":">60% Bone Marrow plasma cells"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"≥ 100 serum free light chain (FLC) ratio"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":">1 focal lesion on MRI"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Hypercalcemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Renal Insufficiency"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"≥ 1 Bone lesion (X-ray, CT, PET)"}],"description":"Participants may have more than one diagnostic characteristic of MM.","paramType":"COUNT_OF_PARTICIPANTS","title":"Multiple Myeloma (MM) Diagnostic Characteristics","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"16"}],"title":"IgG"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"IgA"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"IgD"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"IgE"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"IgM"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Light Chain Only"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Non-secretory"}]}],"description":"Subtype of MM by Immunoglobulin - as determined at Diagnosis","paramType":"COUNT_OF_PARTICIPANTS","title":"MM Subtype - Immunoglobulin (Ig)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}],"title":"Kappa"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Lambda"}]}],"description":"Subtype of MM by involved serum free light chain - as determined at Diagnosis","paramType":"COUNT_OF_PARTICIPANTS","title":"MM Subtype - Involved Serum Free Light Chain","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"R-ISS I"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"R-ISS II"},{"measurements":[{"groupId":"BG000","value":"23"}],"title":"Unknown"}]}],"description":"The Revised International Staging System (R-ISS) is a prognostic staging system used to stratify patients with MM based on genetic risk as assessed by fluorescence in-situ hybridization (FISH) and routinely used lab values. The R-ISS system consists of stage I: serum beta2-microglobulin \\< 3.5 milligram per liter (mg/L), albumin \\>= 3.5 gram per deciliter (g/dL), standard-risk chromosomal abnormalities (CA) by FISH and normal lactate dehydrogenase level (LDH); stage II: neither R-ISS stage I nor stage III; and stage III: beta2-microglobulin \\>= 5.5mg/L and either high-risk CA by FISH or high LDH.","paramType":"COUNT_OF_PARTICIPANTS","title":"R-ISS Score","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"t(4;14)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"t(14;16)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"del(17p)/monosomy 17"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"1q21 gain/amplification"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"t(14;20)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}],"title":"High Risk by IMWG"}],"description":"High-Risk abnormalities identified by cytogenetic testing at diagnosis. International Myeloma Working Group (IMWG)- defined High Risk is the percentage of patients who had any of the following high risk traits: t(4;14), t(14;16), del(17p).","paramType":"COUNT_OF_PARTICIPANTS","title":"High Risk Abnormalities at Diagnosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"t(6;14)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"t(11;14)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"MYC translocation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"TP53 mutation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}],"title":"trisomies/tetrasomies"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"Complex karyotype (when done) or karyotypic del(13)"}],"description":"Standard-Risk abnormalities identified by cytogenetic testing at diagnosis","paramType":"COUNT_OF_PARTICIPANTS","title":"Standard-Risk Abnormalities at Diagnosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"7","value":"4"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Median Number of Lines of Therapy prior to Baseline","unitOfMeasure":"Lines of therapy"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"< 4 Lines of Therapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"≥ 4 Lines of Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Number of Prior Lines of Therapy - categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"Immunomodulatory Agents"},{"categories":[{"measurements":[{"groupId":"BG000","value":"30"}]}],"title":"Proteasome Inhibitors"},{"categories":[{"measurements":[{"groupId":"BG000","value":"29"}]}],"title":"Monoclonal Antibodies"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Conventional Chemotherapy"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Novel Agents"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"Stem Cell Transplant"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Clinical Trials"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Types of Prior Therapy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Double"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Triple"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Quad"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Penta"}]}],"description":"Represents the number of lines patients were refractory to - Double (2 lines), Triple (3), Quad (4) or Penta (5)","paramType":"COUNT_OF_PARTICIPANTS","title":"Type of Refractory MM","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Bladder"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Brain and Spinal Cord"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Breast"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Kidney"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Prostate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Skin Melanoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Uterine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Smoldering MM"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"monoclonalgammopathy of unknown significance"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"History of Prior Malignancy","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Unknown"}]}],"description":"Eastern Cooperative Oncology Group (ECOG) Performance Status as graded by clinician using the following Grades: 0: Fully active, able to carry on all pre-disease performance without restriction. 1: Restricted in physically strenuous activity but ambulatory, able to carry out work of light nature. 2: Ambulatory, capable of self-care, unable to carry out work activities. Up and about more than 50% waking hours. 3: Capable of limited self-care, confined to bed/chair more than 50% waking hours. 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed/chair. 5: Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline ECOG","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Normal"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Mild"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Moderate"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Severe"}]}],"description":"Baseline Renal Impairment - Estimated Glomerular Filtration Rate (eGFR)","paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Renal Impairment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Serum Creatinine ≥ 2.0 mg/dL"},{"measurements":[{"groupId":"BG000","value":"27"}],"title":"Serum Creatinine < 2.0 mg/dL"}]}],"description":"Serum Creatinine levels are used here as a measure of renal function. For this study, renal insufficiency is defined as a baseline serum creatinine level of \\>= 2.0 mg/dL.","paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline Renal Impairment (as measured by Serum Creatinine levels)","unitOfMeasure":"Participants"}]}